NCT02303444 - An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors | Biotech Hunter

Enrollment

667

Participants

Timeline

Start Date

April 8, 2015

Primary Completion Date

June 10, 2020

Study Completion Date

July 24, 2020

Conditions

Thyroid Neoplasms

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients can get sorafenib at any time during study.

DRUG

Other Multikinase inhibitors

Patients can get MKIs at any time during study.

Trial Locations (34)

Birmingham

Los Angeles

Torrance

Aurora

Washington D.C.

Plantation

Atlanta

Honolulu

Chicago

New Orleans

Boston

Ann Arbor

The Bronx

Durham

Philadelphia

Dallas

Multiple Locations